Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 12, 2013
Issued Date -
N/A
app pub date -
Jul 20, 2011
filing date -
Nov 3, 2008
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, method of detecting and treating cancer using the antibodies and fragments are also disclosed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully